Beyond the Numbers: Debiopharm’s Three-Month Acromegaly Formulation Shows Gains in Quality of Life and Treatment Satisfaction

In this episode, Isabelle Petit, senior manager at Debiopharm, a leading development company headquartered in Lausanne, Switzerland, discusses the latest data from a clinical trial of a three-month formulation for acromegaly treatment, highlighting its impact on patient quality of life and treatment satisfaction.  Of particular note were participant satisfaction across all domains and the importance of the patient perspective for trial success.  Learn more from Isabelle’s discussion about how this long-term formulation for acromegaly treatment improves patient satisfaction and yields positive physical and psychological outcomes.